The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 10, 2021

Filed:

May. 24, 2017
Applicant:

Amgen Research (Munich) Gmbh, Munich, DE;

Inventors:

Peter Kufer, Munich, DE;

Dirk Nagorsen, Munich, DE;

Juergen Scheele, Munich, DE;

Gerhard Zugmaier, Munich, DE;

Matthias Klinger, Munich, DE;

Patrick Hoffmann, Munich, DE;

Virginie Naegele, Munich, DE;

Elaine-Pashupati Dopfer, Munich, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/10 (2006.01); A61K 31/65 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 31/10 (2013.01); A61K 31/65 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); G01N 33/5008 (2013.01); C07K 2317/70 (2013.01); G01N 2500/04 (2013.01);
Abstract

The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated.


Find Patent Forward Citations

Loading…